Management of Anemia in Patients with Inflammatory Bowel Disease.
10.4166/kjg.2015.65.3.145
- Author:
Kyeong Ok KIM
1
Author Information
1. Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea. kokim@yu.ac.kr
- Publication Type:Review
- Keywords:
Anemia;
Inflammatory bowel diseases;
Iron deficiency;
Inflammation
- MeSH:
Anemia/*drug therapy/etiology;
Biomarkers/analysis;
Ferritins/analysis;
Hepcidins/analysis;
Humans;
Inflammatory Bowel Diseases/complications/*diagnosis;
Iron/*therapeutic use;
Vitamin B 12/therapeutic use
- From:The Korean Journal of Gastroenterology
2015;65(3):145-150
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Anemia is one of the commonest extraintestinal manifestations of inflammatory bowel disease (IBD). The pathogenesis of anemia in IBD is complex but iron deficiency combined with inflammation is the most common factor related to the development of anemia. However, other causes such as vitamin B12 and folate deficiency, hemolysis, myelosuppression and drug also should not be overlooked. In addition to ferritin, inflammatory markers and new biochemical parameters such as hepcidin and ferritin index are being tested as diagnostic a tool. First step for treatment is disease activity control and iron supplementation. Although oral iron is widely used, intravenous iron therapy should be considered in patients who are intolerant to oral iron therapy, have severe and refractory anemia or are in active disease state. Recently, new intravenous iron formulations have been introduced and due to their safety and easy usage, they have become the standard treatment modality for managing anemia in IBD. Erythropoietin and transfusion can be considered in specific situations. Vitamin B12 and folate supplementation is also important in patients who are deficient of these micronutrients. Since anemia in IBD patients could significantly influence the disease outcome, further studies and standard guideline for IBD are needed.
